02.12.2016

MagForce AG supports NOA Winter School 2016 from December 01-02 in Münster, Germany

  • Team of Prof. Dr. med. Walter Stummer, Director of the Department of Neurosurgery, University of Münster, introduces nanoparticles application technique ‘NanoPaste’

  • Data recently presented at SNO Annual Meeting 2016 in Arizona, USA, indicate strong immune-stimulating potential in addition to tumor ablation

Berlin, Germany and Nevada, USA, December 02, 2016 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced that the Company supports NOA Winter School 2016 held by the Neuro-Oncological Working Group (Neuroonkologische Arbeitsgemeinschaft, NOA) on December 01 and 02, 2016, in Münster, Germany, as one of the main sponsors.

 

Reporting on their experiences with NanoTherm therapy, Dr. med. Johannes Wölfer, Deputy Director of the Neurosurgical Department, Clinic and Policlinic for Neurosurgery, University Hospital Münster and part of the team of Prof. Dr. med. Walter Stummer, Director of the Department of Neurosurgery at the University Hospital Münster and President of the German Neurosurgical Society (DGNC), will hold a presentation titled “Local Hyperthermia as an adjuvant for malignant glioma – NanoPaste and NanoTherm” on Friday, December 02, 2016 at 3pm local time.

 

As winner of the EANS 2016 Best Abstract Award, the team of the University Hospital of Münster will be introducing its new nanoparticles application technique called ‘NanoPaste’ that was developed for the use with NanoTherm thermotherapy in glioblastoma and used first in man at the Department of Neurosurgery in Münster.

 

Furthermore, Dr. Dr. med. Grauer, Associate Professor and Deputy Head of Neuro-Oncology Center at University Hospital Münster, recently presented a poster on the “Inflammatory response after modified NanoTherm and radiotherapy of recurrent glioblastoma” at the 21st Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO). The SNO 2016 Annual Meeting, which, with over 2000 participants, is one of the most important congresses for the Neuro-Oncological community worldwide was held mid-November in Arizona, USA.

 

The presentation at SNO attracted great interest among the conference attendees. Priv.-Doz. Dr. Dr. med. Oliver Grauer explained the approach of the Münster team in more detail: “Immune therapy is currently one of the most interesting approaches in cancer treatment. Therefore it is important to investigate any possible immune-related effect of NanoTherm Therapy in addition to the tumor ablation. In our poster presentation during the SNO conference in November 2016, we reported about our data demonstrating that the combination of modified NanoTherm therapy with radiotherapy can induce a strong reaction at the resection cavity assuming that large amounts of cellular debris are released in situ, which can serve as a source of tumor antigens to elicit host CD8+ T-cell mediated adaptive immune responses against the tumor. These are first observations indicating an immune stimulatory effect of modified NanoTherm therapy in patients. We are very excited about these observations and are aiming to continue investigating this interesting effect during the treatment of further patients to decipher the NanoTherm immune-related effects.”

 

About the NOA Winter School 2016

NOA is the Neuro-Oncological Working Group within the German Cancer Society. For the NOA Winter School 2016, renowned neuro-oncology researchers and clinicians from all over Germany have been invited to share their knowledge. Conference topics will include a wide variety of subjects from advice on “how to deliver bad news” or “how do molecular markers influence therapy decisions?” to “therapy options for meningeoma” to “Medulloblastoma treatment in children and adults” as well as “current developments in the field clinical studies” and “Gliom news”. In addition to presenting latest research results, the NOA Winter School is a platform for exchange and discussion with individual experts and sharing experiences.  

 

About SNO 2016

The Society for Neuro-Oncology (SNO) is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education. Building upon the success of past SNO meetings, the 2016 Scientific Meeting featured concurrent and plenary sessions, highlighted by focused minisymposia, oral abstract presentations, rapid reports, and poster presentations. New this year were the enhanced e-talk poster presentations, “Meet the Experts” and “SNO Daily Highlights” webcasts. Special lunch tutorials and industry-sponsored symposia provided in-depth information on a variety of timely issues impacting CNS tumor research and treatment including the 2016 revision of the WHO classification of CNS tumors and Epigenetics.

The Education Day focused on Precision Medicine and the new WHO classification of CNS tumors and offered innovative and informative presentations in Translational Science, Clinical and Applied Neuro-Oncology. Highlights included mock integrative diagnostic and molecular tumor boards. 

 

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm™ therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

 

NanoTherm™, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm™, NanoPlan®, and NanoActivator® are trademarks of MagForce AG in selected countries.

 

 

For more information, please visit: www.magforce.com        

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list

 

Contact

Barbara von Frankenberg
+49 30 30 83 80-77

 

Disclaimer 

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

 

27.10.2016

MagForce AG participates in four upcoming international conferences in Q4 2016

Berlin, Germany and Nevada, USA, October 27, 2016 - MagForce AG (Frankfurt, Entry Standard, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in four upcoming scientific and investor conferences in the fourth quarter 2016:

 

  • 13th AIO Autumn Convention - Oncology in Internal Medicine Working Group (AIO) – Update Medical Oncology
    Date: November 17-19, 2016
    Location: Berlin, Germany
    Booth: No. 24, level 1
  • 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO)
    Date: November 17-20, 2016
    Location: Scottsdale, Arizona, USA
    Presentation: “Inflammatory response after modified NanoTherm® and radiotherapy of recurrent glioblastoma”
    Presenter: Team of Prof. Dr. med. Walter Stummer, Director of the Clinic for Neurosurgery, University Hospital Münster
    Speaker: Dr. Dr. med. Oliver Grauer, Head of Neuro-Oncology Team, University Hospital Münster
    Date of presentation: Friday, November 18, 2016; Poster session 19:00 MST
  • German Equity Forum
    Date: November 21-23, 2016
    Location: Frankfurt, Germany
    Presentation: Ben J. Lipps, CEO of MagForce AG, Monday, November 21, 2016, 14:00 CET Room: Oslo
  • NOA Winter School 2016 – Neurological Working Group
    Date: December 1-2, 2016
    Location: Münster, Germany
    Presentation: “Local Hyperthermia as an adjuvant for malignant glioblastoma – NanoTherm and NanoPaste”
    Speaker: Dr. med. Johannes Wölfer, Deputy Director of the Neurosurgical Department, Clinic and Policlinic for Neurosurgery, University Hospital Münster
    Date of presentation: Thursday, December 1, 2016, 15:00 CET

 

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm™ therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

 

NanoTherm™, NanoPlan®, and NanoActivator®  are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

 

For more information, please visit: www.magforce.com        

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list

 

 For meeting arrangements or any further questions, please contact us at:

Patient Advocacy

Dr. Katarzyna Zarychta
+49 30 30 83 80-66

Medical Liaison

Dr. Ulrike Boettcher
+49 89 95 477 95-64

Media & Investors

Barbara v. Frankenberg
+49 30 30 83 80-77

Disclaimer      

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

 

11.10.2016

MagForce AG publishes Directors' Dealings

download PDF

 

06.10.2016

MagForce AG publishes Directors' Dealings

download PDF